U.S. health authorities are taking final comments from the public on how to regulate over-the-counter cannabis extracts such as CBD.
The suggestions are due to the U.S. Food and Drug Administration (FDA) by midnight ET Tuesday on how the agency should regulate cannabis-derived products.
The FDA has vowed to expedite its review of cannabis-derived compounds because of a surge in CBD products hitting the market. The agency now says it will have an update on the review by late summer or early fall.
The health regulator has asked the public to share scientific literature and other data to help regulators decide:
- Appropriate CBD dosing levels.
- Drug interactions.
- Impacts to “special populations, like children, the elderly, and pregnant or lactating women.”
- Risks of long-term exposure.
The FDA started its review May 31, hearing from more than 100 industry manufacturers and activists. It said it had received nearly 3,800 additional written comments by Monday.
Subscribe to our Newsletter
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers